Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.47 |
| ▸ | PRKCA | P17252 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28726822 | 0.98 | CYP4F2 (0.46) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL1142630 | 0.93 | CYP4F2 (0.50) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL2724991 | 0.91 | CYP4F2 (0.53) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL2533990 | 0.91 | CYP4F2 (0.53) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL2533277 | 0.91 | CYP4F2 (0.53) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL7989588 | 0.87 | POLB (0.46) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL27819169 | 0.87 | POLB (0.46) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL150006 | 0.85 | PRKCA (0.47) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| SCHEMBL29049106 | 0.85 | POLB (0.44) | CYP4F2CYP4A11PRKCAPOLBGAA | |
| Ammonia Solution, Strong SCHEMBL27804637 | 0.83 | PRKCA (0.45) | CYP4F2CYP4A11PRKCAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9938301-B2 | Dihydropyrimido fused ring derivative as HBV inhibitor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-07-13 | — | — | US | disclosed |
| CN-102421293-A | Substituted nucleoside and nucleotide analogs | ALIOS BIOPHARMA INC | 2012-04-18 | — | — | CN | disclosed |
| EP-0711760-B1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-0882720-B1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-6130332-A | USING A GROUP 8 METAL CATALYST AND ALDEHYDES OR KETONE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| US-6127538-A | HYDROXYALKYLATION OF A TRIAMINO TRIAZINE DERIVATIVE HAVING AT LEAST ONE REACTIVE NITROGEN BY REACTING WHILE HEATING WITH AN ALKANEDIOL OR ITS ADDUCT IN THE PRESENCE OF HYDROGEN AND A METAL CATALYST; BY-PRODUCT INHIBITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| CN-1043896-C | Method for synthetizing phosphoroamidate and its mixture from amines in water system by direct phosphorylating | UNIV QINGHUA (CN) | 1999-06-30 | — | — | CN | disclosed |
| EP-0882720-A1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5792867-A | Method of alkylating of triazine derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0711760-A1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| CN-1095722-A | The method of amine direct phosphorylated synthesizing amino phosphoric acid salt and composition thereof in aqueous systems | UNIV QINGHUA (CN) | 1994-11-30 | — | — | CN | disclosed |
| US-RE34722-E | Antiulcer agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| CN-1079726-A | N-phosphorylated thing and synthetic new method thereof | UNIV QINGHUA (CN) | 1993-12-22 | — | — | CN | disclosed |
| US-4578381-A | ANTIULCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | CYP4F2 1433/4885CYP4A11 277/4885PRKCA 409/4885 |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | TMBIM6, HAVCR2, HDGF | CYP4F2 2480/4885CYP4A11 1587/4885PRKCA 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.